Sensorion reports full-year 2019 financial results and business update Solid €30m cash position at year end and runway increased to beginning of Q3 2021. pdfRead

Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment. pdfRead

Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer. pdfRead

Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study. pdfread

Sensorion announces the full conversion of Sofinnova Partners convertible bonds into ordinary shares. pdfRead